Ignite Creation Date:
2024-05-06 @ 2:08 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04225429
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2024-03-22
First Post:
2020-01-08
Brief Title:
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Sponsor:
Epizyme Inc
Organization:
Ipsen
Study Overview
Official Title:
Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A multicenter open-label expanded access program to provide access to tazemetostat to Epithelioid Sarcoma ES patients in serious need who are otherwise unable to participate in a clinical study or whom access is not available through marketed product in the US
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None